Conflict of interest

The authors declare no conflict of interest.

## Author details

Takeshi Yokoo1,2, Kenya Kamimura2 \*, Tsutomu Kanefuji<sup>3</sup> , Takeshi Suda<sup>3</sup> and Shuji Terai<sup>2</sup>

\*Address all correspondence to: kenya-k@med.niigata-u.ac.jp

1 Department of Preemptive Medicine for Digestive Diseases and Healthy Active Life, Niigata University School of Medicine, Chuo-ku, Niigata, Japan

2 Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Chuo-ku, Niigata, Japan

[11] Siefker-Radtke A, Zhang X, Guo CC, et al. A phase l study of a tumor-targeted systemic nanodelivery system, SGT-94, in genitourinary cancers. Molecular Therapy. 2016;24:1484-

Nucleic Acid-Based Therapy: Development of a Nonviral-Based Delivery Approach

http://dx.doi.org/10.5772/intechopen.80741

[12] Pirollo KF, Nemunaitis J, Leung PK, et al. Safety and efficacy in advanced solid tumors of a targeted nanocomplex carrying the p53 gene used in combination with docetaxel: A phase

[13] Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Human Gene Therapy. 2004;15:

[14] Sweeney P, Karashima T, Ishikura H, et al. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder

[15] Chen W, Li H, Liu Z, et al. Lipopolyplex for therapeutic gene delivery and its application for the treatment of Parkinson's disease. Frontiers in Aging Neuroscience. 2016;8:68. DOI:

[16] Hadinoto K, Sundaresan A, Cheow WS. Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. European Journal of Pharmaceutics

[17] Rezaee M, Oskuee RK, Nassirli H, et al. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. Journal of Controlled Release. 2016;236:1-14.

[18] Hoshino A, Costa-Silva B, Shen T-L, et al. Tumour exosome integrins determine organotropic

[19] Kim SM, Yang Y, Oh SJ, et al. Cancer-derived exosomes as a delivery platform of CRISPR/ Cas9 confer cancer cell tropism-dependent targeting. Journal of Controlled Release. 2017;

[20] Akao Y, Nakagawa Y, Hirata I, et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Therapy. 2010;17:398-408. DOI: 10.1038/cgt.2009.88 [21] Katakowski M, Buller B, Zheng X, et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Letters. 2013;335:201-204. DOI: 10.1016/j.canlet.

[22] Lou G, Song X, Yang F, et al. Exosomes derived from miR-122-modified adipose tissuederived MSCs increase chemosensitivity of hepatocellular carcinoma. Journal of Hematol-

[23] O'Brien K, Lowry MC, Corcoran C, et al. miR-134 in extracellular vesicles reduces triplenegative breast cancer aggression and increases drug sensitivity. Oncotarget. 2015;6:

and Biopharmaceutics. 2013;85:427-443. DOI: 10.1016/j.ejpb.2013.07.002

metastasis. Nature. 2015;527:329-335. DOI: 10.1038/nature15756

ogy & Oncology. 2015;8:122. DOI: 10.1186/s13045-015-0220-7

1b study. Molecular Therapy. 2016;24:1697-1706. DOI: 10.1038/mt.2016.135

1491. DOI: 10.1038/mt.2016.118

10.3389/fnagi.2016.00068

DOI: 10.1016/j.jconrel.2016.06.023

2013.02.019

266:8-16. DOI: 10.1016/j.jconrel.2017.09.013

32774-32789. DOI: 10.18632/oncotarget.5192

1255-1269. DOI: 10.1089/hum.2004.15.1255

cancer model. Cancer Research. 2003;63:4017-4020

3 Department of Gastroenterology and Hepatology, Institute of Community Medicine, Niigata University Medical and Dental Hospital, Minamiuonuma, Niigata, Japan
